Case Report: Fabry disease mimicking coronary artery disease and hypertrophic cardiomyopathy—a 15-year diagnostic delay - Report - MDSpire

Case Report: Fabry disease mimicking coronary artery disease and hypertrophic cardiomyopathy—a 15-year diagnostic delay

  • By

  • Tielang Liang

  • Hongyuan Xu

  • Chuang Huang

  • June 18, 2026

  • 0 min

Share

Clinical Report: Fabry Disease Presenting as Coronary Artery Disease

Overview

This case study details a 60-year-old male with a 15-year history of exertional angina, initially misdiagnosed with coronary artery disease. Diagnostic imaging and genetic testing ultimately revealed Fabry disease, highlighting the importance of recognizing this condition in patients with unexplained cardiac symptoms.

Background

Fabry disease is a rare X-linked lysosomal storage disorder that can present with cardiac symptoms overlapping those of more common conditions like hypertrophic cardiomyopathy and coronary artery disease. The diagnostic delay often exceeds a decade, leading to significant morbidity due to irreversible organ damage. Awareness of Fabry disease as a potential diagnosis in adult patients with unexplained left ventricular hypertrophy is crucial for timely intervention.

Data Highlights

No numerical data or trial data presented in the article.

Key Findings

  • The patient experienced a 15-year delay in the diagnosis of Fabry disease, initially misdiagnosed with coronary artery disease.
  • Cardiac magnetic resonance imaging revealed characteristic findings suggestive of Fabry disease.
  • Plasma α-galactosidase A activity was significantly decreased, confirming the diagnosis.
  • Genetic testing identified a pathogenic variant in the GLA gene.
  • Despite the diagnosis, enzyme replacement therapy was not initiated due to various reasons.
  • Multi-system involvement and imaging findings are critical for diagnosing Fabry disease in patients with cardiac symptoms.

Clinical Implications

Clinicians should maintain a high index of suspicion for Fabry disease in patients presenting with unexplained left ventricular hypertrophy and cardiac symptoms. A structured diagnostic approach, including imaging and genetic testing, is essential to reduce delays in diagnosis and initiate appropriate management.

Conclusion

This case underscores the importance of recognizing Fabry disease in the differential diagnosis of cardiac conditions, particularly in patients with prolonged unexplained symptoms. Early diagnosis and intervention can significantly alter disease progression and improve patient outcomes.

Related Resources & Content

  1. Clinical Research in Cardiology, 2018 -- Assessing the CHA2DS2-VASc Score and Fabry-Specific Score for Predicting Stroke or TIA Incidence in Fabry Disease Patients Lacking Atrial Fibrillation
  2. Frontiers in Cardiovascular Medicine, 2026 -- A novel GDF1 frameshift mutation in a young adult with right coronary artery hypoplasia and myocardial bridging: a case report
  3. Clinical Research in Cardiology, 2016 -- Rare instance of cardiac ATTR amyloidosis associated with situs inversus totalis
  4. Clinical Research in Cardiology, 2020 -- Reduction of cardiac amyloid burden observed through cardiovascular magnetic resonance in a hereditary amyloidosis patient
  5. American College of Cardiology, 2024 -- 2024 AHA/ACC/Multisociety Hypertrophic Cardiomyopathy Guideline: Key Points
  6. Molecular Genetics and Metabolism Reports, 2025 -- Two decades experience: Fabry Outcome Survey provides further confirmation of long-term effectiveness of agalsidase alfa enzyme replacement therapy
  7. PMC, 2024 -- 2024 Update of the TSOC Expert Consensus of Fabry Disease
  8. 2024 AHA/ACC/Multisociety Hypertrophic Cardiomyopathy Guideline: Key Points - American College of Cardiology
  9. Molecular Genetics and Metabolism Reports 43 (2025) 101215
  10. 2024 Update of the TSOC Expert Consensus of Fabry Disease - PMC

Original Source(s)

Related Content